Booster dose with Pfizer or Moderna provide greater impact against Covid-19: study

The booster doses of current covid vaccines offer different protection based on different brands, although overall immunity improves again, according to a study published Friday by The Lancet.

The study was carried out in June in the United Kingdom on a group of 3,000 people, and compared numerous configurations, depending on the vaccine injected initially and the one chosen as a booster.

The patients had received a full initial vaccination schedule, with AstraZeneca O Pfizer/BioNtech.

In the case of Pfizer They received a booster dose at least two months after their regimen. In the case of AstraZeneca they received the third injection at least three months later.

This dose could be of the same brand, or a combination with CureVac, Modern, Novavax, Valneva O Janssen.

Other patients were injected with a placebo.

In virtually all booster settings (except those containing a placebo), participants generated new doses of antibodies, although the Pfizer / Valneva combination did not bring any substantial change.

All vaccines that boosted immunity worked with young and old people, but there are big differences in response depending on the vaccine, “the study authors explained.

Furthermore, the analysis showed several limitations.

On the one hand, the booster dose was administered with a short time lapse compared to the second dose. In some cases, the time between the third and second doses was even shorter than the period between the first and second injections.

And also the study did not measure the true efficacy of vaccines with respect to diseasebut only the reactions of the immune system.

The authors plan to continue monitoring the reaction level of the people who participated in the study between six and eight months after their first doses.

The study also looked at side effects, considered “acceptable” in all settings.

Moderna vaccines provide greater reinforcing impact

The vaccines against Covid-19 manufactured by Pfizer and Modern using mRNA technology provide the greatest boost to antibody levels when administered 10 to 12 weeks after the second dose, according to the British study.

The study “COV-Boost“was quoted by British officials when they announced that it was preferred to use Pfizer and Moderna in the reinforcement campaign of the country, but the data has only been made public now.

The study found that six of the seven boosters examined improved immunity after initial vaccination with the Pfizer-BioNTech vaccine, while all seven increased immunity when administered after two doses of the AstraZeneca.

A third dose will be effective for many of the vaccines we have tested and in many different combinations, “Professor Saul Faust, an immunologist at the University of Southampton and leader of the trial, told reporters.

The study, published late Thursday, found that a full or half dose of Pfizer or a full dose of Moderna give a strong boost both to the levels of antibodies and those of purpose Tregardless of whether the person initially received Pfizer O AstraZeneca.

“The four most widely implemented vaccination regimens in the UK lead to essentially the same levels of immunity and are likely to be equally effective,” said Professor Eleanor Riley, an immunologist at the University of Edinburgh. He also indicated that the data also supported a policy change on reinforcement.

These data support the decision of the JCVI (vaccine committee) earlier this week to advance the booster doses to three months after the second vaccine, “he noted.

When they were administered AstraZeneca, Novavax, Johnson & Johnson and Curevac as boosters, they increased antibody levels for any of the initial vaccines, albeit to a lesser degree, according to the study. However, although Valneva increased antibodies in people initially vaccinated with AstraZeneca, it did not provide a boost for Pfizer.



Reference-www.eleconomista.com.mx

Leave a Comment